Regarding ALL, the HSP90 inhibitor PU-H71 has been shown to be effective in treating T-ALL patients samples that express a high level of NOTCH1 (Notch receptor 1)29, NVP-AUY922 led to a degradation of Tyrosine kinase 2 (TYK2) signaling and T-ALL apoptosis30. Here, HSP90AA1 is linked to acute lymphoblastic leukemia.